Etelcalcetide
An intravenous peptide that lowers parathyroid hormone in people with kidney failure on dialysis
Etelcalcetide is a synthetic peptide that activates the calcium-sensing receptor on the parathyroid glands. Approved as Parsabiv in 2017, it is injected into the dialysis line three times a week to treat secondary hyperparathyroidism.
Manufacturer's recommended dosing (FDA label): 5 mg, Three times weekly at the end of dialysis, Intravenous bolus Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
Typical range2.5–15 mg · three times a week, at the end of hemodialysis Approved labelParsabiv (etelcalcetide) injection US prescribing information (DailyMed set cd270093, effective March 8, 2026)compare across peptides →
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Secondary hyperparathyroidism, a common complication of chronic kidney disease, is marked by high parathyroid hormone. It contributes to calcification outside the skeleton and is associated with higher overall and cardiovascular mortality. Calcimimetics make the parathyroid glands' calcium-sensing receptor more sensitive to calcium, so the glands release less hormone.
Cinacalcet is a calcimimetic taken as a daily tablet. Etelcalcetide, developed as velcalcetide or AMG 416, is a peptide given into the dialysis circuit at the end of each session, so the dose is given by staff rather than remembered at home. In a head-to-head trial in 683 patients it lowered parathyroid hormone more often than cinacalcet; lower blood calcium was its most common effect. Because dialysis is what clears it, its effective half-life is 3 to 4 days and levels build over several weeks.
The label starts at 5 mg three times a week and titrates in 2.5 or 5 mg steps no more often than every 4 weeks, within 2.5 to 15 mg. Calcium must be at or above the lower limit of normal to start, is checked within a week of any change, and the drug is stopped if corrected calcium falls below 7.5 mg/dL or symptoms appear.
Beyond PTH, trials against alfacalcidol have looked at the heart: over a year, left ventricular strain held steady on etelcalcetide while it worsened on alfacalcidol, and left atrial enlargement was slower in the per-protocol analysis. It also lowers FGF23. In a small 36-week study, PTH fell by two-thirds while bone density rose 3% to 7% at the spine and hip, and bone biopsies showed slower turnover. These are surrogate measures, not outcomes.
In practice it keeps working: after a year most patients reached guideline PTH targets, though fewer of those switched from cinacalcet. In another series of switchers, about half reached target, much more often when PTH was 600 to 1,000 pg/mL and the glands showed no signs of autonomy. FDA adverse-event reports cluster in the first month, mostly low calcium. Parsabiv is approved for adults on hemodialysis only; the label says it has not been studied in parathyroid cancer, primary hyperparathyroidism or kidney disease not on dialysis.
Mechanism of Action
Etelcalcetide is a peptide calcimimetic that switches on the parathyroid calcium-sensing receptor, lowering parathyroid hormone.
Calcium-sensing receptor
Binds and activates the parathyroid calcium-sensing receptor, so the glands release less PTH.
Calcium and FGF23 fall
Lower serum calcium is the main effect to monitor; FGF23 also falls (2022 study).
Cleared by dialysis
Effective half-life 3 to 4 days in haemodialysis patients, so levels build over weeks (label 12.3).
Published Research
The studies behind etelcalcetide, read from their PubMed abstracts.
First doses in healthy men
Single intravenous doses of 0.5 to 10 mg lowered parathyroid hormone within 30 minutes and FGF23 by 24 hours, with no nausea, vomiting or diarrhoea; the terminal half-life was 18.4 to 20.0 hours in people with normal kidneys.
Against cinacalcet, 683 patients
Over 26 weeks, 68.2% on etelcalcetide reduced parathyroid hormone by more than 30% against 57.7% on cinacalcet, meeting criteria for both non-inferiority and superiority; 52.4% against 40.2% reduced it by more than half. Decreased blood calcium was the most common adverse effect (68.9% against 59.8%).
Heart strain against alfacalcidol
In a one-year randomised trial in haemodialysis, left ventricular global longitudinal strain worsened on alfacalcidol but stayed stable on etelcalcetide; ejection fraction did not differ.
Left atrial size
In the same comparison with alfacalcidol, left atrial volume index grew about 5 mL/m² less on etelcalcetide, a difference significant only in the per-protocol analysis and linked to changes in left ventricular mass.
FGF23 and calciprotein particles
In haemodialysis patients, etelcalcetide users had significantly lower FGF23 at 6 and 12 weeks than non-users; calciprotein particles fell only when it was combined with calcium rather than vitamin D.
Twelve months in practice
After a year, 87% of patients new to calcimimetics and 58% of those switched from cinacalcet had PTH in the KDIGO target range; some with parathyroid glands over 1,000 mm³ still responded.
FDA adverse-event reports
Among 2,525 FDA reports, hypocalcaemia, gastrointestinal symptoms and cardiovascular events were commonest, clustered in the first 30 days; disproportionality signals for sepsis and other events cannot show causation.
Bone quality over 36 weeks
In 13 haemodialysis patients completing follow-up, PTH fell 67% and bone density rose 3% at the spine, 7% at the femoral neck and 3% at the hip, with a higher trabecular bone score; biopsies in five showed a lower bone formation rate.
Switching from cinacalcet
In patients switched from cinacalcet, 49.7% reached the PTH target; success was 79% with baseline PTH 600 to 1,000 pg/mL against 36% above 1,000, and lower when the parathyroid glands showed signs of autonomy.
Phase 3 in Japanese haemodialysis patients: 155 people
In a 12-week double-blind trial in 155 Japanese haemodialysis patients with secondary hyperparathyroidism, 59.0% on etelcalcetide reached the target parathyroid hormone range against 1.3% on placebo, and 76.9% against 5.2% cut it by at least 30%; calcium, phosphorus and FGF-23 fell, and nausea, vomiting and symptomatic low calcium were mild.
Routine dialysis care in Singapore: 148 patients
In an audit of 148 multi-ethnic patients at community dialysis centres, intact PTH fell 16.8% after four months and the share at target rose from 1.4% to 25.9% by eight months, with no symptomatic hypocalcaemia and a lower calcium-phosphate product.
Against placebo: five trials pooled
Across 1,268 participants, etelcalcetide made a 30% fall in parathyroid hormone far more likely than placebo (relative risk 8.64) and lowered phosphate, with more hypocalcaemia, nausea and vomiting.
One year of treatment
In a 52-week open-label extension, about 68% kept a fall of more than 30% in parathyroid hormone; decreased blood calcium (43.3%) was the most common event, and symptomatic hypocalcaemia occurred in 3.7%.
Pooled safety across five trials
In over 3,000 patient records from placebo-controlled, active-controlled and extension trials, the common events were calcium- and gut-related; hypocalcaemia led to stopping in 1% or fewer.
Effect on FGF23
Etelcalcetide lowered the phosphate hormone FGF23 by a median 56% against a 2% rise on placebo, and by 68% against 41% on cinacalcet; the fall tracked calcium and phosphate rather than parathyroid hormone.
Dosing Data
Parsabiv is given by dialysis staff as an intravenous bolus three times a week at the end of haemodialysis, titrated to PTH and calcium.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Parsabiv (etelcalcetide injection): Injection: 2.5 mg/0.5 mL solution in a single-dose vial. Forms the label lists: single-dose vials.
Source: Parsabiv (etelcalcetide injection) label, section 3 (DailyMed version 15, effective March 8, 2026).
Mixing a vial: a worked example
Nothing to mix: the label gives Parsabiv (etelcalcetide injection) as single-dose vials, ready to use.
Source: Parsabiv (etelcalcetide injection) label, sections 2, 3 and 16 (DailyMed version 15, effective March 8, 2026).
Storage before and after mixing
Before mixing or first use: “Store in the original carton in refrigerator at 2°C to 8°C (36°F to 46°F) to protect from light.” “Once removed from the refrigerator: Do not expose to temperatures above 25°C (77°F).” “Use within 7 days if stored in the original carton.”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Parsabiv (etelcalcetide injection) label, sections 16 and 2 (DailyMed version 15, effective March 8, 2026).
How it is taken
As the approved label gives it: Intravenous bolus (Three times weekly at the end of dialysis; Label: secondary hyperparathyroidism on haemodialysis, starting).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of 3 to 4 days (effective half-life in hemodialysis patients). After about five half-lives almost none is left.
How long the doses were given: Label: secondary hyperparathyroidism on haemodialysis, starting: Titrated; Label: maintenance: Changes no more often than every 4 weeks.
When effects appear: unknown; no source on this page gives a time to effect for Etelcalcetide. Results reported in the studies are under Published Research.
Source: half-life: Parsabiv prescribing information, section 12.3 (DailyMed set cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c, effective March 8, 2026; read October 2, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Decreased blood calcium, the most common effect in every trial; Diarrhoea, nausea and vomiting; Muscle spasms and low phosphate. Full list and cautions ↓
When the label says to stop or get help:
- Upper Gastrointestinal (GI) Bleeding: Patients with risk factors for upper GI bleeding may be at increased risk. Monitor patients and promptly evaluate and treat any suspected GI bleeding.
Source: Parsabiv (etelcalcetide injection) label, boxed warning and section 5 (DailyMed version 15, effective March 8, 2026); the Side Effects section below (“From the studies above”).
Interactions
- cinacalcet or another oral calcium-sensing receptor agonist: risk of severe, life-threatening hypocalcaemia; stop cinacalcet at least 7 days before starting etelcalcetide
- other therapies that lower serum calcium: monitor corrected serum calcium closely
Every peptide's record, with its source: the interaction matrix.
Source: Amgen. PARSABIV (etelcalcetide) injection, US prescribing information, section 5.1. DailyMed version effective March 8, 2026, read October 5, 2026.
Checking what you bought
Unknown: no published independent test of Etelcalcetide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Etelcalcetide's expected mass, 1,048.3 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Parsabiv (etelcalcetide), NDA 208325, first approved February 7, 2017, for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis (Drugs@FDA via openFDA and the Parsabiv label, read October 2, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Parsabiv label (DailyMed, effective March 8, 2026).
Legal Status
Etelcalcetide is approved in the US as Parsabiv.
Frequently Asked Questions
?What is etelcalcetide?
A synthetic peptide that activates the calcium-sensing receptor and lowers parathyroid hormone. It is sold as Parsabiv for secondary hyperparathyroidism in adults on hemodialysis.
?How is it different from cinacalcet?
Cinacalcet is a daily tablet; etelcalcetide is injected into the dialysis line three times a week. Head to head, it lowered parathyroid hormone by more than 30% in 68.2% of patients against 57.7%.
?What is the dose?
The label starts at 5 mg three times a week at the end of dialysis, adjusted between 2.5 and 15 mg by parathyroid hormone and calcium levels.
References
- [fda] US FDA, Drugs@FDA (openFDA): PARSABIV (etelcalcetide), NDA 208325, original approval February 7, 2017, prescription. Read October 2, 2026.
- [fda-pi] FDA. Parsabiv (etelcalcetide) injection US prescribing information (DailyMed set cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c, version 15, effective March 8, 2026). Read October 2, 2026.
- [clinical-trial] Block GA, et al. "Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial." JAMA, 2017;317(2):156-164. PMID: 28097356.
- [pubmed] Zhu Y, et al. "Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials." Clin Nephrol, 2020;94(4):173-180. PMID: 32729818.
- [clinical-trial] Bushinsky DA, et al. "One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism." Nephrol Dial Transplant, 2020;35(10):1769-1778. PMID: 30859218.
- [pubmed] Block GA, et al. "An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism." PLoS One, 2019;14(3):e0213774. PMID: 30875390.
- [clinical-trial] Martin KJ, et al. "Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects." Nephrol Dial Transplant, 2014;29(2):385-92. PMID: 24235081.
- [pubmed] Wolf M, et al. "Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis." Clin Kidney J, 2020;13(1):75-84. PMID: 32082556.
- [clinical-trial] Dörr K, et al. "Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial." J Cardiovasc Magn Reson, 2023;25(1):62. PMID: 37932788.
- [pubmed] Dörr K, et al. "Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients." Cardiorenal Med, 2023;13(1):332-341. PMID: 37729887.
- [pubmed] Hashimoto Y, et al. "Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis." Nephrology (Carlton), 2022;27(9):763-770. PMID: 35749253.
- [pubmed] Morosetti M, et al. "Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study." Int Urol Nephrol, 2023;55(7):1865-1873. PMID: 36790677.
- [pubmed] Zou C, et al. "Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data." Ren Fail, 2025;47(1):2523575. PMID: 40605277.
- [fda-pi] Parsabiv (etelcalcetide) injection US prescribing information (DailyMed set cd270093, version 15, effective March 8, 2026), sections 2.1-2.2; read through openFDA October 6, 2026.
- [pubmed] Khairallah P, et al. "Changes in Bone Quality after Treatment with Etelcalcetide." Clin J Am Soc Nephrol, 2023;18(11):1456-1465. PMID: 37574661.
- [pubmed] Parshina EV, et al. "[Switching patients from cinacalcet to etelcalcetide: evaluation of predictors of efficacy in a retrospective cohort study]." Probl Endokrinol (Mosk), 2026;71(6):4-14. PMID: 41640158.
- [pubmed] Fukagawa M, et al. "A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients." Nephrol Dial Transplant, 2017;32(10):1723-1730. PMID: 28057872.
- [pubmed] Khan BA, et al. "Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore." Cureus, 2023;15(11):e48186. PMID: 38050530.
Sources & Citations
Studies were read from their PubMed abstracts; the Parsabiv label from DailyMed (set cd270093, effective March 8, 2026) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.